WHWK (Whitehawk Therapeutics) Interest Expense: $0.00 Mil (TTM As of Mar. 2026)


WHWK Whitehawk Therapeutics Inc WHWK
38 GF Score
Price $4.19
GF Value $0.27
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Whitehawk Therapeutics Interest Expense?

Whitehawk Therapeutics WHWK -2.56% 38 Interest Expense is $0.00 Mil as of Mar. 2026. GuruFocus rates WHWK with a GF Score™ of 38/100 and a GF Value™ of $0.27 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Whitehawk Therapeutics's interest expense for the three months ended in Mar. 2026 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Whitehawk Therapeutics's Operating Income for the three months ended in Mar. 2026 was $ -23.52 Mil. Whitehawk Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $ 0.00 Mil. Whitehawk Therapeutics has no long-term debt (1). The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.


Whitehawk Therapeutics  (NAS:WHWK) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Whitehawk Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-23.52 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $0.00 Mil.

Whitehawk Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Whitehawk Therapeutics had no long-term debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Whitehawk Therapeutics Inc has no debt.


Whitehawk Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Whitehawk Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Whitehawk Therapeutics Interest Expense Chart

Whitehawk Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -0.67 -0.23 -0.23 -0.15 0.00

Whitehawk Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
WHWK
38GF Score
Whitehawk Therapeutics Inc WHWK
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Whitehawk Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $0.00 Mil mean?
Whitehawk Therapeutics (WHWK) has a Interest Expense of $0.00 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Whitehawk Therapeutics and its competitors.
Is Whitehawk Therapeutics' Interest Expense too high?
Whitehawk Therapeutics' current Interest Expense is $0.00 Mil. Overall, Whitehawk Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Whitehawk Therapeutics' Interest Expense compare to IMUX and TTRX?
Whitehawk Therapeutics' Interest Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Whitehawk Therapeutics and its competitors. Whitehawk Therapeutics's current Interest Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Whitehawk Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Whitehawk Therapeutics (WHWK) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $4.19 — trading 1451.9% above its estimated fair value. The current Interest Expense is $0.00 Mil. Whitehawk Therapeutics' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Whitehawk Therapeutics (WHWK), the current Interest Expense is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Whitehawk Therapeutics (WHWK) Overvalued in 2026?

Based on GuruFocus' analysis, Whitehawk Therapeutics stock appears to be overvalued. The current stock price of $4.19 is trading 1451.9% above its estimated GF Value™ of $0.27. GuruFocus considers Whitehawk Therapeutics to be Significantly Overvalued.

Key valuation signals for WHWK:

  • Interest Expense: $0.00 Mil
  • GF Value™: $0.27 vs. price of $4.19 (1451.9% above fair value)
  • GF Score™: 38/100 with 7 warning signs

No single metric tells the full story. See the WHWK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Whitehawk Therapeutics Business Description

Other Exchanges 3350:Germany
Address 2 Headquarters Plaza East Building, 11th Floor, Morristown, New Jersey, NJ, USA, 07960
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
38GF Score

Get the complete analysis for WHWK

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.19
Price
$0.27
GF Value